专利检索_ .含醚基<img id="id" src="$path$/3399115540/jpggifpegjpeg"/>基[[C07C65-21-2基]]或<img id="id" src="$path$/3399115544/jpggifpegjpeg"/>基专利检索_ .含醚基<img id="id" src="$path$/3399115540/jpggifpegjpeg"/>基[[C07C65-21-2基]]或<img id="id" src="$path$/3399115544/jpggifpegjpeg"/>基专利检索查询_ .含醚基<img id="id" src="$path$/3399115540/jpggifpegjpeg"/>基[[C07C65-21-2基]]或<img id="id" src="$path$/3399115544/jpggifpegjpeg"/>基专利检索查询分析平台

子分类：

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
181	4-페닐-4-옥소-2-부텐산 에스테르 유도체의 제조방법	KR1020047018408	2003-05-14	KR1020050000540A	2005-01-05	이토,이사무; 신토우,타이치
본 발명은 황산 에스테르류, 방향족 탄화수소 및 무수말레인산 유도체를 동시에 또는 연속적으로 반응시키는 것을 특징으로 하는 4-페닐-4-옥소-2-부텐산 에스테르 유도체의 제조방법에 관한 것으로, 이러한 방법에 의해 고순도의 4-페닐-4-옥소-2-부텐산 에스테르 유도체가 공업적 규모에서 단시간에 안정적이며 저비용으로 공급된다.
182	아스파탐 유도체의 제조방법, 이의 결정, 이를 위한신규한 제조 중간체 및 당해 중간체의 제조방법	KR1020027004396	2000-10-04	KR1020020038797A	2002-05-23	가와하라시게루; 나가시마가즈타카; 모리겐이치; 다케모토다다시; 오노에리코
2-할로게노아니솔과 3-메틸크로톤산과의반응으로제조된 3-(3-할로게노-4-메톡시페닐)-3-메틸부티르산으로부터이의할로겐원자를하이드록실기로변환시켜수득할수 있는 3-(3-하이드록시-4-메톡시페닐)-3-메틸부티르산을, 카복실기를포르밀기로변환시키는반응으로써 3-(3-하이드록시-4-메톡시페닐)-3-메틸부틸알데히드를제조한다. 당해알데히드유도체는아스파탐과의환원적알킬화반응에의해, 고감미도감미료로서유용한 N-[N-[3-(3-하이드록시-4-메톡시페닐)-3-메틸부틸]-L-α-아스파틸]-L-페닐알라닌 1-메틸에스테르로용이하면서공업적으로효율적이게유도될수 있으므로, 감미료의제조중간체로서대단히우수하다.
183	살절지 동물용 옥사디아진의 제조	KR1019960705877	1995-04-17	KR100249448B1	2000-04-01	애니스,개리,데이비드; 맥캔,스티븐,프레드릭; 샤피로,라파엘
본 발명은 하기 화학식 (Ⅱ) 또는 (Ⅱa)(여기에서, R ¹ 은 F, Cl 또는 C ₁ -C ₃ 플루오로알콕시이고, R ² 은 C ₁ -C ₃ 알킬이고, R ⁴ 는 H 또는 CO ₂ CH ₂ (C ₆ H ₅ )임)로부터 선택된 중간체의 반응을 포함하는, 키랄 중심에서 라세미체이거나 또는 어느 한 에난티오머를 더 많이 함유하는 살절지 동물용 옥사디아진 및 이들의 중간체의 제조 방법 및 하기에 표시된 화합물을 포함하는 특정한 선택된 중간체 및 이들의 제조 방법에 관한 것이다.
184	벤즈아미도 유도체의 제조방법	KR1019830004251	1983-09-09	KR1019900008316B1	1990-11-12	토마스,드파우리스-2
Substd. benzamides of formula (I) and their salts are prepared. In (I), R is C6-18 alkyl; R1 is H, Cl, Br or C1-3 alkyl; R2 is Cl, Br or C1-3 alkyl. (I) are useful in the treatment of emesis, psychosomatic diseases such as gastric and duodenal ulcer, and psychiatric disorders such as depression, anxiety and, esp. psychoses such as schizophrenia. They have a prolonged time of action.
185	2-메톡시-3, 6-디클로로벤조산의 제법	KR1019810001725	1981-05-19	KR1019850001156B1	1985-08-16	시드니비.리취터
A process for preparing 2-methoxy-3,6-dichlorobenzoic acid of a purity in excess of 95 wt.% comprises reacting a mixt. of 10-90 wt.% 2-methoxy-3,6-dichlorobenzoic acid and 90-10 wt.% 2-methoxy-3,5- dichlorobenzoic acid with an alkanol. The reaction occurs in an inert organic reaction medium in the presence of an acid catalyst, at a temp. sufficiently elevated to remove the esterification water as it forms and, thereafter, recovering the 2-methoxy-3,6-dichlorobenzoic acid.
186	N-(피페리디닐-알킬)-카복스아미드의 제조방법	KR1019840001204	1984-03-09	KR1019840008321A	1984-12-14	시바-가이기코오포레이션
내용없음.
187	디 페닐 벤조산염의 제조 방법	KR1019820005889	1982-12-30	KR1019840002767A	1984-07-16	장끌로드뒤브와-5
내용없음.
188	치환된 페닐- 사이클로 프로판 카복실산 에스테르의 제조 방법	KR1019820003184	1982-07-16	KR1019840000498A	1984-02-22	라이너푸크스-4
내용없음
189	N-아릴벤즈아미드 유도체의 제조방법	KR1019810003473	1981-09-15	KR1019830007593A	1983-11-04	케네트와인부로우쥬니어
내용없음
190	2-메톡시-3, 6-디클로로벤조산의 제법	KR1019810001725	1981-05-19	KR1019830006159A	1983-09-17	시드니비.리취터
내용없음
191	LABILE ESTERS OF AGROCHEMICALS FOR CONTROLLED RELEASE AND REDUCTION OF OFF-SITE MOVEMENT	US15913030	2018-03-06	US20180258025A1	2018-09-13	David A. Morgenstern
The present invention relates to esters of carboxylic acid agrochemicals comprising a labile protecting group and having formula (I). Certain of the esters of carboxylic acid agrochemicals do not undergo hydrolysis to a significant degree in the dark, but are cleaved to regenerate the parent carboxylic acid agrochemical when exposed to light. Others of the esters of carboxylic acid agrochemicals undergo hydrolysis under both light and dark conditions. The present invention further relates to methods for the controlled release of a carboxylic acid agrochemicals, and to methods of controlling unwanted plants comprising applying to the unwanted plants an ester of a carboxylic acid agrochemical.
192	Production of organic materials using oxidative hydrothermal dissolution method	US13488092	2012-06-04	US10023512B2	2018-07-17	Kenneth B. Anderson; John C. Crelling; William W. Huggett; Derek M. Perry
Methods of producing organic materials, and in particular methods of producing petroleum materials and organic compounds such as aromatic acids, phenols, and aliphatic poly-carboxylic acids using an oxidative hydrothermal dissolution (OHD) process are disclosed.
193	Process for preparation of herbicidal carboxylic acid salts	US15032298	2014-06-19	US10011552B2	2018-07-03	James Timothy Bristow
A process for preparing a herbicidally active carboxylic acid salt is disclosed. The process comprises the steps of: i) combining a carboxylic acid with a high-boiling, water-immiscible organic solvent to obtain a solution or slurry; ii) treating the solution or slurry produced in step (i) with a base to form a carboxylic acid salt; iii) removing solvent from the mixture produced in step (ii) to obtain a carboxylic acid salt cake; and v) drying the cake obtained in step (iii). The process is particularly suitable for preparing a salt of dicamba.
194	Zinc cluster compounds and their use as catalysts in the reaction of amines with dialkyl carbonates	US14890053	2014-05-19	US09988344B2	2018-06-05	Thorsten Dreier; Stefan Wershofen; Anton Vidal; Robert Haak
The present invention relates to metallic zinc cluster compounds which are suitable as catalysts in the reaction of amines with dialkyl carbonates to produce carbamates. The invention is also directed towards a method for the alkoxycarbonylation of amines. The cluster compound has a general formula which may be written as [M(O2C—R)2]x.[MO]y.[H2O]z, wherein M is Zn, R is an unsubstituted or substituted aromatic, cycloaliphatic, linear aliphatic, or other organic rest, x is 1, y is ≥x is 1, y is ≥0.03 to ≤26.0 and z is >0.00 to ≤17.0.
195	IRE-1α inhibitors	US15356292	2016-11-18	US09981901B2	2018-05-29	John B. Patterson; David G. Lonergan; Gary A. Flynn; Qingping Zeng; Peter V. Pallai
Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
196	Compound	US14980754	2015-12-28	US09975881B2	2018-05-22	Stephen Connolly; Mark Richard Ebden; Iain Alastair Stewart Walters; Thomas Langer; Alan Robert Steven; Craig Robert Stewart; Paula Margaret Tomlin; Andrew John Williams
There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.
197	Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity	US15597516	2017-05-17	US20180085327A1	2018-03-29	Thomas G. Gant; Sepshr Sarshar
Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.
198	Process for Making 2,5-Dihalogenated Phenol	US15311951	2015-05-18	US20170174603A1	2017-06-22	Andreas PLETSCH; Nicole HOLUB; Thomas ULRICH; Petr KVITA; Laurent CAVIN
The present invention relates to a process for reacting chemical compounds comprising the step of reacting a compound of formula (IV) wherein Hal is independently selected from CI or Br, and X″ is a monovalent anion, in the presence of an inorganic acid, wherein the aqueous inorganic acid has a concentration of at least about 60%, at a temperature of about 140° C. to Cabout 250° C., to obtain a compound of formula (V) wherein Hal is as defined above.
199	IRE-1alpha INHIBITORS	US15356292	2016-11-18	US20170152206A1	2017-06-01	John B. Patterson; David G. Lonergan; Gary A. Flynn; Qingping Zeng; Peter V. Pallai
Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
200	Retro-aldol reaction products and methods of making and using same	US14773372	2014-03-07	US09573876B2	2017-02-21	Richard Blair
The presently disclosed and/or claimed inventive concept(s) relates generally to retro-aldol reaction products and methods of making and using same. More particularly, but without limitation, the methods disclosed herein for producing the retro-aldol reaction products are performed in a non-aqueous/solvent-free based process. The reaction products obtained from the process include, for example, dihydroxyacetone, glyceraldehyde, glycolaldehyde, and combinations thereof. In one particular embodiment, the process of making such retro-aldol reaction products includes, without limitation, the step of mechanocatalytically reacting a heterogeneous catalyst with one or more sugar reactants.

5 6 7 8 9 10 11 12 13 14

该功能需要专业版企业版VIP权限，您可以：